# Teclens

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/teclens

- Industry: Healthcare Specialists
- Headquarters: Stamford, US
- Website: www.teclens.com
- Total disclosed funding: $24M
- Latest round: Series A (Aug 25, 2026)
- Investors on record: 5

## About

Founded in 2013 by Roy S. Chuck and others and based in Connecticut, US, Teclens, Inc. focuses on the development of vision correction technologies within the healthcare sector. In August 2026, Teclens, Inc. raised USD 10 million in series A funding from Johnson & Johnson Innovation. The round was part of larger USD 19.3 million series A funding. As of June 2026, the company is led by its CEO, Madhu Ayyagari. The company's primary focus is on developing crosslinking technology that addresses keratoconus and corrects vision errors in healthy eyes. TECLens’ Quantitative Corneal Cross-linking (qCXL) technology has the potential to reshape the cornea for various applications, including the recovery of reading distance vision in presbyopia patients, control of progressive myopia in children, and correction of adult vision errors such as hyperopia and low-order myopia. The firm also develops the CXLens® device, which is a device that emits patterned ultraviolet light and uses ultrasound to measure real-time changes in corneal biomechanics. The CXLens' scleral lens is designed to track eye movement that allows patients to move their eyes, head, or even close their eyes during treatment. The company will use the August 2026 funding to advance clinical trials, develop its next-generation system, and support regulatory submissions.

## Funding rounds

- Series A, Aug 25, 2026, $10M — Johnson & Johnson Innovation
- Series A, Feb 11, 2025, $9.3M — Johnson & Johnson Innovation, Rimonci Capital, Yonjin Venture, Sunmed Capital
- Series A, May 30, 2024, $4.3M — Johnson & Johnson Innovation, Yonghua Capital, Rimonci Capital, Sunmed Capital

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Rimonci Capital (https://capitalatlas.ai/funds/rimonci-capital) — Series A
- Sunmed Capital (https://capitalatlas.ai/funds/sunmed-capital) — Series A
- Yonjin Venture (https://capitalatlas.ai/funds/yonjin-venture) — Series A